|
A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP). |
|
|
Travel, Accommodations, Expenses - MSD |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Innate Pharma |
Research Funding - Innate Pharma |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; MSD; Roche |
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst) |
Expert Testimony - Bristol-Myers Squibb; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche |